Overall, CSTP’s integrative theme of impact analysis draws on the team’s expertise in tobacco product toxicity, user behavior, abuse liability and prospective cohort survey techniques. We seek to provide FDA with hypothesis-driven data regarding advanced generation ECIGs and test predictions about some potential regulations now, while developing a model that can be used to shape, refine and predict the effects of many potential regulatory actions in the future.

This research was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U54DA036105 and the Center for Tobacco Products of the U.S. Food and Drug Administration. The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH or the FDA.